{
  "pattern_analysis": {
    "total_poor_boundaries": 147,
    "content_patterns": {
      "document_separator": 1,
      "has_numeric_marker": 146
    },
    "starting_patterns": {
      "separator": 1,
      "numeric_marker": 146
    },
    "length_stats": {
      "min": 9,
      "max": 765,
      "avg": 92.6938775510204
    }
  },
  "quality_analysis": {
    "total_boundaries": 187,
    "good_boundaries": 38,
    "poor_boundaries": 8,
    "average_quality": 0.5272727272727274,
    "score_distribution": {
      "0.5": 85,
      "0.3": 26,
      "0.9": 20,
      "0.4": 15,
      "0.6": 15,
      "0.7": 11,
      "0.2": 7,
      "0.8": 4,
      "1.0": 3,
      "0.0": 1
    },
    "quality_percentage": {
      "good": 20.32085561497326,
      "poor": 4.27807486631016
    }
  },
  "problematic_sections": [
    {
      "start_chunk": 0,
      "end_chunk": 17,
      "issue_count": 18,
      "chunk_previews": [
        {
          "chunk_index": 0,
          "preview": "====== 文档开始 ======"
        },
        {
          "chunk_index": 1,
          "preview": "<15># 版权所有，侵权必究！"
        },
        {
          "chunk_index": 2,
          "preview": "<27># 中国临床肿瘤学会指南工作委员会"
        },
        {
          "chunk_index": 3,
          "preview": "<50># 专家组成员（以姓氏汉语拼音为序）"
        },
        {
          "chunk_index": 4,
          "preview": "<74>孙涛 辽宁省肿瘤医院（内科）"
        },
        {
          "chunk_index": 5,
          "preview": "<97>CSCO 诊疗指南证据类别·1"
        },
        {
          "chunk_index": 6,
          "preview": "<118># 目录"
        },
        {
          "chunk_index": 7,
          "preview": "<144># 六、乳腺癌脑转移·132"
        },
        {
          "chunk_index": 8,
          "preview": "<163># 八、生物类似药·187"
        },
        {
          "chunk_index": 9,
          "preview": "<181>CSCO诊疗指南推荐等级"
        },
        {
          "chunk_index": 10,
          "preview": "<187># 一、乳腺癌的诊断及检查"
        },
        {
          "chunk_index": 11,
          "preview": "<221># （五）激素受体阳性乳腺癌新辅助治疗"
        },
        {
          "chunk_index": 12,
          "preview": "<237># （四）激素受体阳性乳腺癌辅助治疗"
        },
        {
          "chunk_index": 13,
          "preview": "<251># （三）三阴性晚期乳腺癌解救治疗"
        },
        {
          "chunk_index": 14,
          "preview": "<267># （五）HER-2低表达晚期乳腺癌解救治疗"
        },
        {
          "chunk_index": 15,
          "preview": "<283># 【注释】"
        },
        {
          "chunk_index": 16,
          "preview": "<293># （二）病理学诊断"
        },
        {
          "chunk_index": 17,
          "preview": "<297># 【注释】"
        }
      ]
    },
    {
      "start_chunk": 23,
      "end_chunk": 25,
      "issue_count": 3,
      "chunk_previews": [
        {
          "chunk_index": 23,
          "preview": "<340># PD-L1免疫组化判读评估"
        },
        {
          "chunk_index": 24,
          "preview": "<348># 【注释】"
        },
        {
          "chunk_index": 25,
          "preview": "<357># 乳腺浸润性癌（未经新辅助治疗）TILs评估标准"
        }
      ]
    },
    {
      "start_chunk": 30,
      "end_chunk": 32,
      "issue_count": 3,
      "chunk_previews": [
        {
          "chunk_index": 30,
          "preview": "<400># 【注释】"
        },
        {
          "chunk_index": 31,
          "preview": "<408># 二、乳腺癌的术前新辅助治疗"
        },
        {
          "chunk_index": 32,
          "preview": "<414># 【注释】"
        }
      ]
    },
    {
      "start_chunk": 38,
      "end_chunk": 41,
      "issue_count": 4,
      "chunk_previews": [
        {
          "chunk_index": 38,
          "preview": "<469>HER-2阳性乳腺癌术前治疗常用方案"
        },
        {
          "chunk_index": 39,
          "preview": "<497># 【注释】"
        },
        {
          "chunk_index": 40,
          "preview": "<505># （四）三阴性乳腺癌新辅助治疗"
        },
        {
          "chunk_index": 41,
          "preview": "<525># 【注释】"
        }
      ]
    },
    {
      "start_chunk": 43,
      "end_chunk": 47,
      "issue_count": 5,
      "chunk_previews": [
        {
          "chunk_index": 43,
          "preview": "<537>新辅助治疗常用方案"
        },
        {
          "chunk_index": 44,
          "preview": "<561># 新辅助治疗后三阴性患者的辅助治疗1"
        },
        {
          "chunk_index": 45,
          "preview": "<573># 【注释】"
        },
        {
          "chunk_index": 46,
          "preview": "<599># 【注释】"
        },
        {
          "chunk_index": 47,
          "preview": "<610># 【注释】"
        }
      ]
    },
    {
      "start_chunk": 52,
      "end_chunk": 55,
      "issue_count": 4,
      "chunk_previews": [
        {
          "chunk_index": 52,
          "preview": "<645>HER-2阳性辅助治疗常用方案"
        },
        {
          "chunk_index": 53,
          "preview": "<661># ·TH（周疗紫杉醇 $^ +$ 曲妥珠单抗）"
        },
        {
          "chunk_index": 54,
          "preview": "<675>2.后续强化"
        },
        {
          "chunk_index": 55,
          "preview": "<687>（3）化疗时应注意化疗药物的给药顺序、输注时间和剂量强度，严格按照药品说明和配伍禁忌"
        }
      ]
    },
    {
      "start_chunk": 57,
      "end_chunk": 61,
      "issue_count": 5,
      "chunk_previews": [
        {
          "chunk_index": 57,
          "preview": "<701>10 既往临床研究中，AC或AC-T方案中的蒽环类以多柔比星为主。但考虑到药物可及性，结合"
        },
        {
          "chunk_index": 58,
          "preview": "<705>辅助化疗常用方案（续）"
        },
        {
          "chunk_index": 59,
          "preview": "<723># 【注释】"
        },
        {
          "chunk_index": 60,
          "preview": "<732>（2）对于ER弱阳性患者（阳性率1%\\~10%），其生物学行为与ER阴性相似，因此不建议放"
        },
        {
          "chunk_index": 61,
          "preview": "<758>（2）后续强化"
        }
      ]
    },
    {
      "start_chunk": 81,
      "end_chunk": 89,
      "issue_count": 9,
      "chunk_previews": [
        {
          "chunk_index": 81,
          "preview": "<900>2.T.紫杉类药物，含白蛋白紫杉醇、多西他赛、紫杉醇。"
        },
        {
          "chunk_index": 82,
          "preview": "<917>（3）EMILIA研究证实，相对于拉帕替尼联合卡培他滨，单药T-DM1治疗有显著的PFS和"
        },
        {
          "chunk_index": 83,
          "preview": "<921>（5）HER2CLIMB研究显示，在局部晚期不可切除或转移性HER-2阳性乳腺癌患者中，与"
        },
        {
          "chunk_index": 84,
          "preview": "<935>复发转移性乳腺癌曲妥珠单抗联用的方案"
        },
        {
          "chunk_index": 85,
          "preview": "<957># 解救化疗（续）"
        },
        {
          "chunk_index": 86,
          "preview": "<972># 【注释】"
        },
        {
          "chunk_index": 87,
          "preview": "<982>（4）每个方案的持续时间（周期数）和能否接受多线化疗，应根据患者的具体情况进行个体化选择。"
        },
        {
          "chunk_index": 88,
          "preview": "<995>8ASCENT研究人组了既往接受过二线及以上化疗的晚期三阴性乳腺癌患者，随机分组分别接受戈"
        },
        {
          "chunk_index": 89,
          "preview": "<1005>（2）关于合理的治疗周期，有限的资料显示，持续化疗相对于短期化疗更能延长无进展生存期，甚"
        }
      ]
    },
    {
      "start_chunk": 94,
      "end_chunk": 106,
      "issue_count": 13,
      "chunk_previews": [
        {
          "chunk_index": 94,
          "preview": "<1061>（1）原发性内分泌耐药：辅助内分泌治疗时间2年内复发，或晚期一线内分泌治疗6个月内出现疾"
        },
        {
          "chunk_index": 95,
          "preview": "<1068>（2）MONARCH2研究中约70%患者为经AI治疗进展，结果证实阿贝西利联合氟维司群，"
        },
        {
          "chunk_index": 96,
          "preview": "<1074>（4）MONALEESA-3研究显示，在氟维司群基础上联合瑞波西利，mPFS显著延长（2"
        },
        {
          "chunk_index": 97,
          "preview": "<1080>（7）BOLERO-2研究证实，在非甾体AI治疗失败后，依西美坦联合依维莫司较单用依西美"
        },
        {
          "chunk_index": 98,
          "preview": "<1086>（9）对于完成AI辅助治疗停药大于12个月复发的患者可以使用AI；但对于停药12个月内复"
        },
        {
          "chunk_index": 99,
          "preview": "<1090># 2.激素受体阳性晚期乳腺癌的解救化疗"
        },
        {
          "chunk_index": 100,
          "preview": "<1098># 1.激素受体阳性HER-2低表达"
        },
        {
          "chunk_index": 101,
          "preview": "<1102># 【注释】"
        },
        {
          "chunk_index": 102,
          "preview": "<1113># 2.激素受体阴性HER-2低表达"
        },
        {
          "chunk_index": 103,
          "preview": "<1117># 五、乳腺癌骨转移"
        },
        {
          "chunk_index": 104,
          "preview": "<1127>4.PET/CT可以在临床早期发现骨转移的异常信号，灵敏度和特异度都很高，但需要在PET"
        },
        {
          "chunk_index": 105,
          "preview": "<1146>（2）地舒单抗 $1 2 0 \\mathrm { m g }$ ，皮下注射，每4周给药1"
        },
        {
          "chunk_index": 106,
          "preview": "<1160>乳腺癌单纯骨转移不是可测量病灶，但是可以通过CT（骨窗）或X线摄片评价其疗效，所以应当将"
        }
      ]
    },
    {
      "start_chunk": 111,
      "end_chunk": 113,
      "issue_count": 3,
      "chunk_previews": [
        {
          "chunk_index": 111,
          "preview": "<1210>2.PET/CT能够反映肿瘤及正常组织的代谢差异，有助于肿瘤诊断，但是对脑内较小的转移灶"
        },
        {
          "chunk_index": 112,
          "preview": "<1218># 1.乳腺癌脑转移局部治疗推荐"
        },
        {
          "chunk_index": 113,
          "preview": "<1222># 2.乳腺癌脑转移抗HER-2靶向药物治疗推荐"
        }
      ]
    },
    {
      "start_chunk": 116,
      "end_chunk": 121,
      "issue_count": 6,
      "chunk_previews": [
        {
          "chunk_index": 116,
          "preview": "<1244>8 对症支持治疗是乳腺癌脑转移的重要治疗手段，可以改善患者生活质量，有助于放疗和药物治疗"
        },
        {
          "chunk_index": 117,
          "preview": "<1252># 2.治疗药物致吐风险分级"
        },
        {
          "chunk_index": 118,
          "preview": "<1269>（2）中致吐风险静脉治疗（ ${ \\mathrm { 5 - H T } } _ { 3"
        },
        {
          "chunk_index": 119,
          "preview": "<1279># （二）骨髓抑制的预防和治疗［102]"
        },
        {
          "chunk_index": 120,
          "preview": "<1289># 【注释】"
        },
        {
          "chunk_index": 121,
          "preview": "<1297># 2.化疗导致的血红蛋白水平下降"
        }
      ]
    },
    {
      "start_chunk": 124,
      "end_chunk": 138,
      "issue_count": 15,
      "chunk_previews": [
        {
          "chunk_index": 124,
          "preview": "<1313>3.化疗导致的血小板减少"
        },
        {
          "chunk_index": 125,
          "preview": "<1317># 【注释】"
        },
        {
          "chunk_index": 126,
          "preview": "<1328># （三）心脏安全性管理［132]"
        },
        {
          "chunk_index": 127,
          "preview": "<1370>（2）小分子TKI：虽然小分子TKI的心功能不全及LVEF下降风险较低，但仍推荐在治疗前"
        },
        {
          "chunk_index": 128,
          "preview": "<1378># （四）内分泌药物耐受性及用药注意事项"
        },
        {
          "chunk_index": 129,
          "preview": "<1390># 3.乳腺癌患者可能因生理或使用药物因素出现卵巢功能下降，而引起绝经相关症状、泌尿生殖"
        },
        {
          "chunk_index": 130,
          "preview": "<1398># 1.TKI相关性腹泻"
        },
        {
          "chunk_index": 131,
          "preview": "<1404>（2）TKI相关性腹泻的预防：治疗前应教育患者，告知可能出现的腹泻症状，指导患者每日记录"
        },
        {
          "chunk_index": 132,
          "preview": "<1414><table><tr><td>奈拉替尼用药时间</td><td>洛哌丁胺剂量</td><"
        },
        {
          "chunk_index": 133,
          "preview": "<1418># 2.TKI相关皮肤不良反应"
        },
        {
          "chunk_index": 134,
          "preview": "<1428># （六）CDK4/6抑制剂不良反应管理"
        },
        {
          "chunk_index": 135,
          "preview": "<1436>2.CDK4/6抑制剂导致中性粒细胞减少症的剂量调整和治疗"
        },
        {
          "chunk_index": 136,
          "preview": "<1444># 3.CDK4/6抑制剂相关腹泻"
        },
        {
          "chunk_index": 137,
          "preview": "<1452># 5.CDK4/6抑制剂相关静脉血栓栓塞"
        },
        {
          "chunk_index": 138,
          "preview": "<1464># （七）西达本胺不良反应管理［136]"
        }
      ]
    },
    {
      "start_chunk": 147,
      "end_chunk": 149,
      "issue_count": 3,
      "chunk_previews": [
        {
          "chunk_index": 147,
          "preview": "<1559># 1.营养风险筛查"
        },
        {
          "chunk_index": 148,
          "preview": "<1567># 【注释】"
        },
        {
          "chunk_index": 149,
          "preview": "<1576># 【注释】"
        }
      ]
    },
    {
      "start_chunk": 151,
      "end_chunk": 186,
      "issue_count": 36,
      "chunk_previews": [
        {
          "chunk_index": 151,
          "preview": "<1620>（2）药物治疗：需要根据患者的皮肤不良反应类型、严重程度、患者的整体身体状况等因素，以及"
        },
        {
          "chunk_index": 152,
          "preview": "<1636># 八、生物类似药"
        },
        {
          "chunk_index": 153,
          "preview": "<1646># 九、临床研究"
        },
        {
          "chunk_index": 154,
          "preview": "<1652># 2.乳腺癌临床研究的设计、实施和报告"
        },
        {
          "chunk_index": 155,
          "preview": "<1656># 十、真实世界研究"
        },
        {
          "chunk_index": 156,
          "preview": "<1668># 3.真实世界研究的设计类型"
        },
        {
          "chunk_index": 157,
          "preview": "<1676># 1.术前新辅助治疗的患者管理"
        },
        {
          "chunk_index": 158,
          "preview": "<1686># 3.复发转移性乳腺癌患者的管理"
        },
        {
          "chunk_index": 159,
          "preview": "<1696># 4.特殊时期的患者管理"
        },
        {
          "chunk_index": 160,
          "preview": "<1706>（1）CTC：CTC是指从恶性肿瘤原发部位脱落，通过血管或淋巴系统进入血液循环的细胞，其"
        },
        {
          "chunk_index": 161,
          "preview": "<1710>（2）ctDNA：ctDNA是肿瘤细胞凋亡、坏死之后释放到外周血中的游离DNA，片段长度"
        },
        {
          "chunk_index": 162,
          "preview": "<1716># 2.循环肿瘤标志物的检测技术"
        },
        {
          "chunk_index": 163,
          "preview": "<1726>（2）dPCR：dPCR是第三代PCR技术，其原理与传统的荧光定量PCR类似，只是将检测"
        },
        {
          "chunk_index": 164,
          "preview": "<1734># 1.智能影像助力肿瘤诊断与治疗评价"
        },
        {
          "chunk_index": 165,
          "preview": "<1742># 3.智能决策丰富临床实践的决策模式"
        },
        {
          "chunk_index": 166,
          "preview": "<1755>[6]ALLISONKH,HAMMONDM,OWSETTM,etal.Estrogena"
        },
        {
          "chunk_index": 167,
          "preview": "<1762>[13]CHENX C,JIAO DC,QIAOJH,etal. De-escalate"
        },
        {
          "chunk_index": 168,
          "preview": "<1767>[18]WANGF,WANG Y,XIONG B,etal.Neoadjuvant py"
        },
        {
          "chunk_index": 169,
          "preview": "<1772>[23] CHENL,LIH,ZHANG H,etal.Camrelizumab vs "
        },
        {
          "chunk_index": 170,
          "preview": "<1778>[29] CARDOSOF,VAN'TVEERLJ,BOGAERTSJ,etal.70-"
        },
        {
          "chunk_index": 171,
          "preview": "<1784>[35] WANGX,WANG SS,HUANGH,etal.Efectofcapeci"
        },
        {
          "chunk_index": 172,
          "preview": "<1789>[40]P PAGANI O,WALLEYBA,FLEMING GF,etal.Adju"
        },
        {
          "chunk_index": 173,
          "preview": "<1794>[45」OFFERSENB V,ALSNERJ,NIELSENHM,etal.Parti"
        },
        {
          "chunk_index": 174,
          "preview": "<1799>[50]F KUNKLERIH,WILLIAMSLJ,JACKWJL,etal.Brea"
        },
        {
          "chunk_index": 175,
          "preview": "<1804>[55] KIMYB,BYUHK,KIMDY,etal.Efectofelectivei"
        },
        {
          "chunk_index": 176,
          "preview": "<1810>[61]JAGSI R,BARLOW WE,WOODWARD WA,et al. Rad"
        },
        {
          "chunk_index": 177,
          "preview": "<1815>[66]XIE J,XUF,ZHAO Y,etal.Hypofractionated v"
        },
        {
          "chunk_index": 178,
          "preview": "<1820>[71]CAOL,OUD,QI W X,et al.A randomized trial"
        },
        {
          "chunk_index": 179,
          "preview": "<1826>[77]Y YAOH,YANM,TONGZetalSafety,effcacyandph"
        },
        {
          "chunk_index": 180,
          "preview": "<1831>[82]RUGO HS,IMSA,CARDOSOF,etal.Efcacyof marg"
        },
        {
          "chunk_index": 181,
          "preview": "<1837>[88]ROBSONME,TUNGN,CONTEP,etal. OlympiADfina"
        },
        {
          "chunk_index": 182,
          "preview": "<1843>[94] BARDIA A,HURVITZ SA,TOLANEY SM,et al.Sa"
        },
        {
          "chunk_index": 183,
          "preview": "<1849>[100]HONGRX,XUF,XIA W,etal.Metronomiccapecit"
        },
        {
          "chunk_index": 184,
          "preview": "<1854>[105] SLEDGE GWJR,TOIM,NEVENP,etal.MONARCH2:"
        },
        {
          "chunk_index": 185,
          "preview": "<1859>[110] YARDLEYDA,NOGUCHI S,PRITCHARDKI, et al"
        },
        {
          "chunk_index": 186,
          "preview": "<1863>[114] KALINSKYK,ACCORDINOMK,CHUZANC,etal.Ran"
        }
      ]
    }
  ],
  "boundary_count": 2099,
  "recommendations": [
    "🔧 优化数字标记边界检测：大量分块包含<数字>标记但边界质量差，建议改进数字标记的边界优先级算法"
  ]
}